Collaboration Enables Rapid Advancement of Rare Lung Disease Therapy to Human Trials

Bruce Trapnell, MD, suspected that an inhaled medication could help treat patients with autoimmune pulmonary alveolar proteinosis (aPAP), a rare, potentially deadly lung disease.

Trapnell reached out to NCATS, an NIH program, which helped shepherd the potential therapy through several steps of the drug development process, ultimately enabling a clinical trial in aPAP patients.

Learn more at National Institutes of Health.

 

Topics:

Cincinnati Children's News Team

About the Author: Cincinnati Children's News Team

The members of the news team at Cincinnati Children's are responsible for telling the stories of the medical center. Stories of the families we serve, research and clinical care, safe and healthy practices and happenings at the hospital. If it has to do with Cincinnati Children's, Danielle, Nick, Jim, Kate, Rachel, Terry and Shannon will keep you informed.

Write a comment

Your data will be safe! Your e-mail address will not be published. Also other data will not be shared with third person. Required fields marked as *

Comments

No Comments Yet! You can be first to comment on this post!